NCT00670553已完成1 期

A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer

Novartis Pharmaceuticals1 个研究点分布在 1 个国家目标入组 7 人开始时间: 2008年9月最近更新: 2017年5月17日

研究概览

简要总结

The purpose of this study is to assess the feasibility of combined administration of different LBH589 dosages with radiotherapy in order to establish the dosage to be evaluated in future studies.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究组 & 干预措施

LBH589

Experimental

干预措施: panobinostat (Drug)

结局指标

主要结局

Establish Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)

时间窗: 1 to 28 days

次要结局

Safety profile of oral LBH589 when given in combination with standard Radiotherapy(min 1 month)

研究者

发起方

Novartis Pharmaceuticals

申办方类型

Industry

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

已完成

1 期

LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid TumorsSolid Tumors

NCT00556088SCRI Development Innovations, LLC40

已完成

1 期

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After CastrationProstate CancerProstatic Neoplasms

NCT00878436NYU Langone Health52

已完成

1 期

Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract CancersHead and Neck CancerLung Cancer

NCT00738751H. Lee Moffitt Cancer Center and Research Institute44

进行中（未招募）

不适用

A phase Ib/IIa, trial of LBH589 in combination with trastuzumab in adult female patients with HER2 positive metastatic breast cancer whose disease has progressed during or following therapy with trastuzumab - NDmetastatic breast cancer

EUCTR2007-002449-19-ITOVARTIS FARMA118